Clinical Immunotherapeutics

, Volume 1, Issue 6, pp 441–448

Immunogenicity of Pulmonary Surfactant Preparations

Implications for Therapy of Respiratory Distress Syndrome
  • David S. Strayer
Review Article Disease Treatment Review

Summary

The increasing use of natural and synthetic surfactants to treat neonatal respiratory distress syndrome (RDS), and the likely extension of their use to other conditions, demands an understanding of the potential consequences of surfactant therapy. In particular, the ability of the body to produce antibodies against autologous or administered surfactants carries important long term implications that should be considered in planning treatment.

The proteins of natural surfactants and the phospholipids of natural and synthetic surfactants are both antigenic. Administered surfactant is immunogenic as administered, i.e. via the intratracheal route of instillation. Antibodies against surfactant constituents can inactivate surfactant in vitro and in vivo. The work of a number of groups suggests that at least some infants with neonatal RDS produce antibodies against surfactant constituents, although the role of these antibodies in the pathogenesis of RDS or its complications is still unclear. In addition, the presence of antibodies against surfactant might lead to future immunologically mediated damage. Circulating antibodies may inactivate surfactant following a primary lung injury however caused, and thus exacerbate the respiratory embarrassment caused by the primary insult.

Therefore, until more definitive data are available it is wise to assume that surfactant therapy is not without potential complications. One must safeguard against overconfident or indiscriminate use of surfactants. Exogenous surfactant therapy is effective in reducing the mortality of neonatal RDS; its use should be extended to other illnesses only after careful and controlled clinical trials.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959; 97: 517–23Google Scholar
  2. 2.
    Notter RH, Shapiro DL, Ohning B, et al. Biophysical activity of synthetic phospholipids combined with purified lung surfactant 6000 dalton apoprotein. Chem Phys Lipids 1987; 44: 1–17PubMedCrossRefGoogle Scholar
  3. 3.
    Possmayer F. A proposed nomenclature for pulmonary surfactant-associated proteins. AmRev Respir Dis 1988; 138: 990–8CrossRefGoogle Scholar
  4. 4.
    Cockshutt AM, Weitz J, Possmayer F. Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry 1990; 29: 8424–9PubMedCrossRefGoogle Scholar
  5. 5.
    Nogee LM, De Mello D, Dehner LP, et al. Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med 1993; 328: 406–10PubMedCrossRefGoogle Scholar
  6. 6.
    Crouch E, Parghi D, Kuan SF, et al. Surfactant protein D: subcellular localization in nonciliated bronchiolar epithelial cells. Am J Physiol 1992; 263: L60–6PubMedGoogle Scholar
  7. 7.
    Taneva S, Keough KMW. Pulmonary surfactant proteins SP-B and SP-C in spread monolayers at the air-water interface. I Monolayers of pulmonary surfactant protein SP-B and phospholipids. Biophys J 1994; 66: 1137–48PubMedCrossRefGoogle Scholar
  8. 8.
    Taneva S, Keough KMW. Pulmonary surfactant proteins SP-B and SP-C in spread monolayers at the air-water interface. II. Monolayers of pulmonary surfactant protein SP-C and phospholipids. Biophys J 1994; 66: 1149–57PubMedCrossRefGoogle Scholar
  9. 9.
    Taneva S, Keough KMW. Pulmonary surfactant proteins SP-B and SP-C in spread monolayers at the air-water interface. III. Proteins SP-B plus SP-C with phospholipids in spread monolayers. Biophys J 1994; 66: 1158–66PubMedCrossRefGoogle Scholar
  10. 10.
    Strayer DS, Hallman M, Merritt TA. Immunogenicity of surfactant. I. Human alveolar surfactant. Clin Exp Immunol 1991; 83: 35–40PubMedCrossRefGoogle Scholar
  11. 11.
    Strayer DS, Hallman M, Merritt TA. Immunogenicity of surfactant. II Porcine and bovine surfactants. Clin Exp Immunol 1991; 83: 41–46PubMedCrossRefGoogle Scholar
  12. 12.
    Strayer DS, Merritt TA, Makunike C, et al. Antigenicity of low molecular weight surfactant species. Am J Pathol 1989; 134: 723–32PubMedGoogle Scholar
  13. 13.
    Rott IM, Donaich D. Gastric autoimmunity. In: Miescher PA, Muller-Eberhard HJ, editors. Textbook of Immunopathology. New York: Grune & Stratton, 1976: 737–49Google Scholar
  14. 14.
    Thivolet J, Beyvin AJ. Recherches par immunofluorescence d’autoahticorps sérique vis-à-vis des constituents de l’épiderme chez les brulés. Experientia 1968; 24: 945–6PubMedCrossRefGoogle Scholar
  15. 15.
    Shahani SK, Hattikudor NS. Immunological consequences of vasectomy. Arch Androl 1981; 7: 193–9PubMedCrossRefGoogle Scholar
  16. 16.
    Boehme MW, Kataaha PK, Holborow EL. Autoantibodies to intermediate filaments in sera of patients with Schistosoma mansoni infection. Clin Exp Immunol 1989; 77: 230–3PubMedGoogle Scholar
  17. 17.
    Ziegler AG, Herskowitz RD, Jackson RA, et al. Predicting type I diabetes. Diabetes Care 1990; 13: 762–5PubMedCrossRefGoogle Scholar
  18. 18.
    McEvoy RC, Witt ME, Ginsberg-Fellner F, et al. Anti-insulin antibodies in children with type I diabetes mellitus: genetic regulation of production and presence at diagnosis before insulin replacement. Diabetes 1986; 35: 634–41PubMedCrossRefGoogle Scholar
  19. 19.
    Strayer DS, Vitetta ES, Kohler H. Anti-receptor antibody I. Isolation and characterization of the immunoglobulin receptor for phosphorylcholine. J Immunol 1975; 114: 722–7PubMedGoogle Scholar
  20. 20.
    Sinisi L, Palma V, Mansi D. Antiphospholipid antibodies in young adults with cerebrovascular ischemic disease. Acta Neurol 1992; 14: 381–6Google Scholar
  21. 21.
    Bick RL, Baker WF. Anticardiolipin antibodies and thrombosis. Hematol Oncol Clin North Am 1992; 6: 1287–99PubMedGoogle Scholar
  22. 22.
    Bartmann P, Bamberger U, Pohlandt F, et al. Immunogenicity and immunomodulatory activity of bovine surfactant (SF-RI 1). Acta Paediatr Scand 1992; 81: 383–8CrossRefGoogle Scholar
  23. 23.
    Settmacher U, Volk HD, Jahn S, et al. Polyclonal Stimulation of human B lymphocytes derived from fetal liver and spleen cells at different stages of ontogeny. Immunol Lett 1990; 26: 159–63PubMedCrossRefGoogle Scholar
  24. 24.
    Van Es JH, Raaphorst FM, van Tol MJ, et al. Expression pattern of the most JH-proximal human VH gene segment (VH6) in the B cell and antibody repertoire suggests a role of VH6-encoded IgM antibodies in early ontogeny. J Immunol 1993; 150: 161–8PubMedGoogle Scholar
  25. 25.
    Campana D, Janossy G, Coustan-Smith E, et al. The expression of T cell receptor-associated proteins during T cell ontogeny in man. J Immunol 1989; 142: 57–66PubMedGoogle Scholar
  26. 26.
    Sell S. Immunology, Immunopathology and Immunity. New York: Elsevier, 1987Google Scholar
  27. 27.
    Strayer DS, Merritt TA, Lwebuga-Mukasa J, et al. Surfactant-anti-surfactant immune complexes in neonatal respiratory distress syndrome. Am J Pathol 1986; 122: 353–62PubMedGoogle Scholar
  28. 28.
    Germuth EG Jr. A comparative histologic and immunologic study in rabbits of induced hypersensitivity of the serum sickness type. J Exp Med 1953; 97: 257–82PubMedCrossRefGoogle Scholar
  29. 29.
    Whitsett JA, Hull WM, Luse S. Failure to detect surfactant protein-specific antibodies in sera of premature infants treated with Survanta, a modified bovine surfactant. Pediatrics 1991; 87: 505–10PubMedGoogle Scholar
  30. 30.
    Chida S, Phelps DS, Soll RF, et al. Surfactant proteins and anti-surfactant antibodies in sera from infants with respiratory distress syndrome with and without surfactant treatment. Pediatrics 1991; 88: 84–9PubMedGoogle Scholar
  31. 31.
    Robertson B, Kobayashi T, Ganzuka M, et al. Experimental neonatal respiratory failure induced by monoclonal antibodies to the hydrophobic surfactant-associated protein SP-B. Pediatr Res 1991; 30: 239–43PubMedCrossRefGoogle Scholar
  32. 32.
    Cummings JJ, Holm BA, Hudak ML, et al. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs. Am Rev Respir Dis 1992; 145: 999–1004PubMedCrossRefGoogle Scholar
  33. 33.
    Rider EA, Jobe AH, Ikegami M, et al. Different ventilation strategies alter surfactant in preterm rabbits. J Appl Physiol 1992; 73: 2089–96PubMedGoogle Scholar

Copyright information

© Adis international Limited 1994

Authors and Affiliations

  • David S. Strayer
    • 1
  1. 1.Department of Pathology and Cell BiologyJefferson Medical CollegePhiladelphiaUSA

Personalised recommendations